Advances in Research on Malignant Transformation of Endometriosis-associated Ovarian Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Oct 24

PMID 39445058

Authors

Fang Chen

Mengying Zhu

Wenjuan Li

Affiliations

Soon will be listed here.

Abstract

Endometriosis (EMs) is a prevalent chronic gynecological condition that depends on estrogen, marked by the presence of active endometrial tissue (glands and stroma) outside the uterus. Although pathologically benign, it exhibits biological behaviors such as invasion and metastasis akin to malignant tumors. Endometriosis-associated ovarian carcinoma (EAOC), arising from malignant transformation of EMs, poses significant clinical challenges. However, the mechanisms underlying EAOC pathogenesis remain incompletely understood, with a lack of reliable biomarkers for early diagnosis and personalized treatment strategies. Considering the significant number of EMs patients and the extended period during which malignant transformation can occur, EAOC deserves significant attention. Current research both domestically and internationally indicates that the pathogenesis of EAOC is complex, involving genetic mutations, immune microenvironment, oxidative stress, epigenetic changes, and related areas. This review summarizes the mechanisms underlying the development of EAOC.

References

Chen P, Li B, Ou-Yang L . Role of estrogen receptors in health and disease. Front Endocrinol (Lausanne). 2022; 13:839005. PMC: 9433670. DOI: 10.3389/fendo.2022.839005. View

Zeng Z, Fu M, Hu Y, Wei Y, Wei X, Luo M . Regulation and signaling pathways in cancer stem cells: implications for targeted therapy for cancer. Mol Cancer. 2023; 22(1):172. PMC: 10583419. DOI: 10.1186/s12943-023-01877-w. View

Schnack T, Oliveira D, Christiansen A, Hogdall C, Hogdall E . Prognostic impact of molecular profiles and molecular signatures in clear cell ovarian cancer. Cancer Genet. 2023; 278-279:9-16. DOI: 10.1016/j.cancergen.2023.08.001. View

Taylor H, Laurence A, Uhlig H . The Role of PTEN in Innate and Adaptive Immunity. Cold Spring Harb Perspect Med. 2019; 9(12). PMC: 6886458. DOI: 10.1101/cshperspect.a036996. View

Alsop K, Fereday S, Meldrum C, DeFazio A, Emmanuel C, George J . BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol. 2012; 30(21):2654-63. PMC: 3413277. DOI: 10.1200/JCO.2011.39.8545. View

Barreta A, Sarian L, Ferracini A, Bastos Eloy Costa L, Mazzola P, de Angelo Andrade L . Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis. Hum Pathol. 2018; 85:72-81. DOI: 10.1016/j.humpath.2018.10.028. View

Li S, Meersma G, Kupryjanczyk J, de Jong S, Wisman G . Genome-wide DNA methylation in relation to ARID1A deficiency in ovarian clear cell carcinoma. J Transl Med. 2024; 22(1):556. PMC: 11163774. DOI: 10.1186/s12967-024-05311-7. View

Clower L, Fleshman T, Geldenhuys W, Santanam N . Targeting Oxidative Stress Involved in Endometriosis and Its Pain. Biomolecules. 2022; 12(8). PMC: 9405905. DOI: 10.3390/biom12081055. View

Ledermann J, Oza A, Lorusso D, Aghajanian C, Oaknin A, Dean A . Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020; 21(5):710-722. PMC: 8210534. DOI: 10.1016/S1470-2045(20)30061-9. View

10.

Throwba P.K H, Unnikrishnan L, Pangath M, Vasudevan K, Jayaraman S, Li M . The epigenetic correlation among ovarian cancer, endometriosis and PCOS: A review. Crit Rev Oncol Hematol. 2022; 180:103852. DOI: 10.1016/j.critrevonc.2022.103852. View

11.

Li B, Duan H, Wang S, Li Y . Ferroptosis resistance mechanisms in endometriosis for diagnostic model establishment. Reprod Biomed Online. 2021; 43(1):127-138. DOI: 10.1016/j.rbmo.2021.04.002. View

12.

Zubrzycka A, Zubrzycki M, Perdas E, Zubrzycka M . Genetic, Epigenetic, and Steroidogenic Modulation Mechanisms in Endometriosis. J Clin Med. 2020; 9(5). PMC: 7291215. DOI: 10.3390/jcm9051309. View

13.

Carmen M . Evidence for the Relationship Between Endometriosis and Epithelial Ovarian Cancer. Obstet Gynecol Surv. 2015; 70(9):587-95. DOI: 10.1097/OGX.0000000000000218. View

14.

Kato A, Romero M . Regulation of electroneutral NaCl absorption by the small intestine. Annu Rev Physiol. 2010; 73:261-81. PMC: 3988668. DOI: 10.1146/annurev-physiol-012110-142244. View

15.

Barlin J, Dao F, Bou Zgheib N, Ferguson S, Sabbatini P, Hensley M . Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol. 2012; 125(3):621-4. DOI: 10.1016/j.ygyno.2012.03.027. View

16.

Dymanowska-Dyjak I, Frankowska K, Abramiuk M, Polak G . Oxidative Imbalance in Endometriosis-Related Infertility-The Therapeutic Role of Antioxidants. Int J Mol Sci. 2024; 25(12). PMC: 11204103. DOI: 10.3390/ijms25126298. View

17.

Chan J, Brady M, Penson R, Huang H, Birrer M, Walker J . Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. N Engl J Med. 2016; 374(8):738-48. PMC: 5081077. DOI: 10.1056/NEJMoa1505067. View

18.

Wu J, Xie H, Yao S, Liang Y . Macrophage and nerve interaction in endometriosis. J Neuroinflammation. 2017; 14(1):53. PMC: 5351283. DOI: 10.1186/s12974-017-0828-3. View

19.

van Driel W, Koole S, Sikorska K, Schagen van Leeuwen J, Schreuder H, Hermans R . Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N Engl J Med. 2018; 378(3):230-240. DOI: 10.1056/NEJMoa1708618. View

20.

Nanda A, K T, Banerjee P, Dutta M, Wangdi T, Sharma P . Cytokines, Angiogenesis, and Extracellular Matrix Degradation are Augmented by Oxidative Stress in Endometriosis. Ann Lab Med. 2020; 40(5):390-397. PMC: 7169633. DOI: 10.3343/alm.2020.40.5.390. View